ERS/ATS 2017 guideline: preventing COPD exacerbations

Who it applies to

Adults with COPD who have a history of exacerbations, managed in outpatient and primary/specialist care settings.

Key recommendations

• Long-acting muscarinic antagonists (LAMAs) are recommended over long-acting beta-agonists (LABAs) for reducing exacerbations in patients with a history of exacerbations.
  conditional
• Combination LABA/LAMA therapy is suggested over LAMA or LABA monotherapy for exacerbation prevention in appropriate patients.
  conditional
• Inhaled corticosteroids added to LABA are suggested for patients with continued exacerbations despite long-acting bronchodilator therapy, weighing benefit against pneumonia risk.
  conditional
• Triple therapy (LABA/LAMA/ICS) may be considered in patients with repeated exacerbations who are not controlled on dual therapy.
  conditional
• Roflumilast is suggested in patients with chronic bronchitis, severe airflow limitation, and frequent exacerbations, particularly in those on triple inhaled therapy who continue to exacerbate.
  conditional
• Long-term macrolide therapy (e.g., azithromycin) is suggested as an option for patients with frequent exacerbations despite optimal inhaled therapy, balancing benefit against antimicrobial resistance and cardiac/hearing risks.
  conditional
• Mucolytic agents are suggested for reducing exacerbations in selected patients, particularly those with chronic bronchitis.
  conditional
• The guideline advises against the routine use of oral corticosteroids for exacerbation prevention outside of acute exacerbation treatment.
  conditional against
• Long-term home oxygen therapy is not recommended solely for the purpose of preventing exacerbations in patients who do not otherwise meet criteria for oxygen therapy.
  conditional against
• The guideline suggests against initiating pulmonary rehabilitation within 4 weeks of hospital discharge following an acute exacerbation, pending further evidence on timing and safety.
  conditional against
• Influenza vaccination was noted as an established standard-of-care practice for COPD patients rather than a formally graded recommendation in this guideline.

Practice points for students

• Most recommendations in this guideline are conditional/weak, reflecting moderate-to-low quality evidence rather than strong certainty, which is an important exam point about GRADE-based guidelines.
• LAMA is preferred over LABA as initial long-acting bronchodilator choice specifically for exacerbation prevention, not necessarily for symptom control.
• Escalation to ICS-containing regimens should be reserved for patients with ongoing exacerbations despite bronchodilator therapy, given pneumonia risk with ICS.
• Roflumilast and macrolides are considered add-on options for a specific phenotype: frequent exacerbators with chronic bronchitis who remain uncontrolled on inhaled therapy.
• The guideline does not support long-term oxygen, routine oral corticosteroids, or early post-discharge pulmonary rehabilitation as exacerbation-prevention strategies.

Condition

Other guidelines on this topic

• 2023 Canadian Thoracic Society Guideline on Pharmacotherapy in Patients With Stable COPDCHEST2023Summary
• Long-Term Noninvasive Ventilation in Chronic Stable Hypercapnic Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice GuidelineATS2020Summary
• Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115)NICE2019Summary

Independent educational summary written by the WhiteCoat Pro editorial team with AI assistance and checked by a second AI model. It does not reproduce the guideline text, tables or figures, and it is not affiliated with or endorsed by ERS. It is not medical advice: always read the original guideline before applying it to patients.